Lubomir Sokol, MD, PhD
Researcher

Lubomir Sokol, MD, PhD

Academic Rank: Senior Member

Overview

Dr. Sokol's laboratory research has been recognized in the field of molecular biology of primary polycythemias and more recently also in the pathobiology of bone marrow failure disorders including T-cell LGL leukemia and MDS.  

Discipline

    • Malignant Hematology
    • Chemical Biology and Molecular Medicine Program
    • Center for Infection Research in Cancer

Education & Training

    • Charles University of Prague, Czechoslovakia, MD
    • Charles University of Prague, Czechoslovakia, PhD
    • Charles University of Prague, Czechoslovakia, Resident - Radiation Oncology
    • Charles University of Prague, Czechoslovakia, Fellow - Radiation Oncology
    • Charles University of Prague, Czechoslovakia, Fellow - Clinical Oncology
    • Czechoslovak Academy of Sciences, Prague, Czechoslovakia, Postdoctoral Fellow - Molecular Genetics
    • University of Alabama, Birmingham, AL, Postdoctoral Fellow - Molecular Biology
    • Louisiana State University, Lafayette, LA, Resident - Internal Medicine
    • University of South Florida, Tampa, FL, Fellow - Medical Oncology/Hematology
Research

T/NK cell lymphoma/leukemia, Large Granular Lymphocytic Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Polycythemia/Familial Erythrocytosis, Myelodysplastic syndromes, Paroxysmal Nocturnal Hemoglobinuria

Publications

  • Foss F, Horwitz S, Pro B, Miles Prince H, Sokol L, Balser B, Wolfson J, Coiffier B. Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol. 2017 Sep;10(1):154. Pubmedid: 28923081. Pmcid: PMC5603163.
  • Shustov A, Coiffier B, Horwitz S, Sokol L, Pro B, Wolfson J, Balser B, Eisch R, Popplewell L, Prince HM, Allen SL, Piekarz R, Bates S. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. Leuk Lymphoma. 2017 Oct;58(10):2335-2341. Pubmedid: 28264616.
  • Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, Cherry MA, Bashir Q, Darrah J, Nishihori T, Sibai H, Hamadani M, de Lima M, Gerds AT, Selby G, Qazilbash MH, Forman SJ, Ayala E, Lipton JH, Hari PN, Muzzafar T, Zhang L, Olteanu H, Perkins J, Sokol L, Kumar A, Ahmed S. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. Brit J Haematol. 2017 Oct. Pubmedid: 28980314.
  • Bohra C, Sokol L, Dalia S. Progressive Multifocal Leukoencephalopathy and Monoclonal Antibodies: A Review. Cancer Control. 2017 Oct;24(4). Pubmedid: 28975841.
  • Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Ma. Biol Blood Marrow Tr. 2017 Nov;23(11):1826-1838. Pubmedid: 28797780.
  • Visweshwar N, Jaglal M, Sokol L, Zuckerman K. Chemotherapy-related anemia. Ann Hematol. 2017 Nov. Pubmedid: 29103107.
  • Juárez-Salcedo LM, Sandoval-Sus J, Sokol L, Chavez JC, Dalia S. The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now. Crit Rev Oncol Hematol. 2017 May;113:52-62. Pubmedid: 28427522.
  • Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017. J Natl Compr Canc Ne. 2017 Mar;15(3):293-311. Pubmedid: 28275031.
  • Foss F, Pro B, Miles Prince H, Sokol L, Caballero D, Horwitz S, Coiffier B. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Med. 2017 Jan;6(1):36-44. Pubmedid: 27981793. Pmcid: PMC5269566.
  • Zhang L, Van den Bergh M, Sokol L. CD4-Positive T-Cell Large Granular Lymphocytosis Mimicking Sezary Syndrome in a Patient With Mycosis Fungoides. Cancer Control. 2017 Apr;24(2):207-212. Pubmedid: 28441377.
  • Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Porcu P. NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. J Natl Compr Canc Ne. 2016 Sep;14(9):1067-1079. Pubmedid: 27587620.
  • Ozoya OO, Sokol L, Dalia S. EBV-Related Malignancies, Outcomes and Novel Prevention Strategies. Infect Disord Drug Targets. 2016 May;16(1):4-21. Pubmedid: 27052336.
  • Foss F, Horwitz S, Pro B, Prince HM, Sokol L, Balser B, Wolfson J, Coiffier B. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol. 2016 Mar;9:22. Pubmedid: 26965915. Pmcid: PMC4785666.
  • Basiorka AA, McGraw KL, De Ceuninck L, Griner LN, Zhang L, Clark JA, Caceres G, Sokol L, Komrokji RS, Reuther GW, Wei S, Tavernier J, List AF. Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41. Cancer Res. 2016 Jun;76(12):3531-3540. Pubmedid: 27197154. Pmcid: PMC4911265.
  • Apuri S, Sokol L. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma. Expert Opin Inv Drug. 2016 Jun;25(6):687-696. Pubmedid: 26954526.
  • Jeong D, Choi JW, Jeong K, Sokol L. CT findings associated with blastic plasmacytoid dendritic cell neoplasm: a case report. Acta Radiol Open. 2016 Jul;5(7):2058460116657688. Pubmedid: 27504192. Pmcid: PMC4963986.
  • Pro B, Horwitz SM, Prince HM, Foss FM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Iyer SP, Shustov AR, Wolfson J, Balser BE, Coiffier B. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Hematol Oncol. 2016 Jul. Pubmedid: 27402335.
  • Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Diffuse Large B-Cell Lymphoma Version 1.2016. J Natl Compr Canc Ne. 2016 Feb;14(2):196-231. Pubmedid: 26850490.
  • Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. 2016 Dec;128(25):2960-2975. Pubmedid: 27737891. Pmcid: PMC5179338.
  • Roe C, Komrokji R, Zhang L, Price S, Sokol L. Adult T-Cell Leukemia/Lymphoma: Rarely Encountered in the United States. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S191-S194. Pubmedid: 27521318.
  • Chavez JC, Sandoval-Sus J, Horna P, Dalia S, Bello C, Chevernick P, Sotomayor EM, Sokol L, Shah B. Lymphomatoid Granulomatosis: A Single Institution Experience and Review of the Literature. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S170-S174. Pubmedid: 27521314.
  • Chavez JC, Piris-Villaespesa M, Dalia S, Powers J, Turba E, Nodzon L, Komrokji R, Sokol L, Locke FL, Lancet J, Sotomayor EM, Kharfan-Dabaja MA, Pinilla-Ibarz J. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leuk Res. 2016 Aug;47:78-83. Pubmedid: 27285853.
  • Zhang X, Sokol L, Bennett JM, Moscinski LC, List A, Zhang L. T-cell large granular lymphocyte proliferation in myelodysplastic syndromes: Clinicopathological features and prognostic significance. Leuk Res. 2016 Apr;43:18-23. Pubmedid: 26927701.
  • McGraw KL, Cluzeau T, Sallman DA, Basiorka AA, Irvine BA, Zhang L, Epling-Burnette PK, Rollison DE, Mallo M, Sokol L, Solé F, Maciejewski J, List AF. TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes. Oncotarget. 2015 Oct;6(33):34437-34445. Pubmedid: 26416416. Pmcid: PMC4741464.
  • Ozoya OO, Sokol L, Dalia S. "EBV-related Malignancies, Outcomes and Novel Prevention Strategies". Infect Disord Drug Targets. 2015 Nov. Pubmedid: 26585986.
  • Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman MR, Ballerini R, Liu L, Kim YH. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015 Mar;125(12):1883-1889. Pubmedid: 25605368. Pmcid: PMC4375715.
  • Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wilson L, Yahalom J, Zafar N, Dwyer M, Sundar H. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J Natl Compr Canc Ne. 2015 Mar;13(3):326-362. Pubmedid: 25736010. Pmcid: PMC4841457.
  • McGraw KL, Zhang LM, Rollison DE, Basiorka AA, Fulp W, Rawal B, Jerez A, Billingsley DL, Lin HY, Kurtin SE, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, Calasanz MJ, Cervera J, Such E, González T, Nevill TJ, Haferlach T, Smith AE, Kulasekararaj A, Mufti G, Karsan A, Maciejewski JP, Sokol L, Epling-Burnette PK, Wei S, List AF. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes. Blood Cancer J. 2015 Mar;5:e291. Pubmedid: 25768405. Pmcid: PMC4382654.
  • Roe C, Bennett J, Zhang L, Chavez J, Shah B, Sokol L, Komrokji R. Hemophagocytic Lymphohistiocytosis in Malignant Hematology: Uncommon but Should Not Be Forgotten?. Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S147-S150. Pubmedid: 26297268.
  • Horna P, Kurant D, Sokol L, Sotomayor EM, Moscinski L, Glass LF. Flow cytometric identification of immunophenotypically aberrant T-cell clusters on skin shave biopsy specimens from patients with mycosis fungoides. Am J Clin Pathol. 2015 Jun;143(6):785-796. Pubmedid: 25972320.
  • Dalia S, Suleiman Y, Croy DW, Sokol L. Association of Lymphomagenesis and the Reactivation of Hepatitis B Virus in Non-Hodgkin Lymphoma. Cancer Control. 2015 Jul;22(3):360-365. Pubmedid: 26351893.
  • Dalia S, Price S, Forsyth P, Sokol L, Jaglal M. What is the optimal dose of high-dose methotrexate in the initial treatment of primary central nervous system lymphoma?. Leuk Lymphoma. 2015 Feb;56(2):500-502. Pubmedid: 24882264.
  • Dalia S, Dunker K, Sokol L, Mhaskar R. Hepatitis B seropositivity and risk of developing multiple myeloma or Hodgkin lymphoma: A meta-analysis of observational studies. Leuk Res. 2015 Dec;39(12):1325-1333. Pubmedid: 26394533.
  • Braue J, Hagele T, Yacoub AT, Mannivanan S, Sokol L, Glass F, Greene JN. A case of rupioid syphilis masquerading as aggressive cutaneous lymphoma. Mediterr J Hematol Infect Dis. 2015 Apr;7(1):e2015026. Pubmedid: 25960854. Pmcid: PMC4418386.
  • Foss F, Coiffier B, Horwitz S, Pro B, Prince HM, Sokol L, Greenwood M, Lerner A, Caballero D, Baran E, Kim E, Nichols J, Balser B, Wolfson J, Whittaker S. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomark Res. 2014 Sep;2:16. Pubmedid: 25279222. Pmcid: PMC4181623.
  • Zhang L, Ramchandren RM, Papenhausen P, Loughran TP, Sokol L. Transformed aggressive γδ-variant T-cell large granular lymphocytic leukemia with acquired copy neutral loss of heterozygosity at 17q11.2q25.3 and additional aberrations. Eur J Haematol. 2014 Sep;93(3):260-264. Pubmedid: 24635703.
  • Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's lymphomas, version 4.2014. J Natl Compr Canc Ne. 2014 Sep;12(9):1282-1303. Pubmedid: 25190696. Pmcid: PMC4839265.
  • Luria L, Nguyen J, Zhou J, Jaglal M, Sokol L, Messina JL, Coppola D, Zhang L. Manifestations of gastrointestinal plasmablastic lymphoma: a case series with literature review. World J Gastroenterol. 2014 Sep;20(33):11894-11903. Pubmedid: 25206297. Pmcid: PMC4155383.
  • Dalia S, Sagatys E, Sokol L, Kubal T. Rosai-dorfman disease: tumor biology, clinical features, pathology, and treatment. Cancer Control. 2014 Oct;21(4):322-327. Pubmedid: 25310213.
  • Deaver D, Horna P, Cualing H, Sokol L. Pathogenesis, diagnosis, and management of kikuchi-fujimoto disease. Cancer Control. 2014 Oct;21(4):313-321. Pubmedid: 25310212.
  • Riaz W, Zhang L, Horna P, Sokol L. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. Cancer Control. 2014 Oct;21(4):279-289. Pubmedid: 25310209.
  • Dalia S, Shao H, Sagatys E, Cualing H, Sokol L. Dendritic cell and histiocytic neoplasms: biology, diagnosis, and treatment. Cancer Control. 2014 Oct;21(4):290-300. Pubmedid: 25310210.
  • Sokol L. Hope for orphan lymphoproliferative and histiocytic diseases on the horizon?. Cancer Control. 2014 Oct;21(4):260-261. Pubmedid: 25310207.
  • Zhang L, Zhou J, Sokol L. Hereditary and acquired hemophagocytic lymphohistiocytosis. Cancer Control. 2014 Oct;21(4):301-312. Pubmedid: 25310211.
  • Dalia S, Jaglal M, Chervenick P, Cualing H, Sokol L. Clinicopathologic characteristics and outcomes of histiocytic and dendritic cell neoplasms: the moffitt cancer center experience over the last twenty five years. Cancers (Basel). 2014 Nov;6(4):2275-2295. Pubmedid: 25405526. Pmcid: PMC4276966.
  • Horna P, Deaver DM, Qin D, Moscinski LC, Sotomayor EM, Glass LF, Sokol L. Quantitative flow cytometric identification of aberrant T cell clusters in erythrodermic cutaneous T cell lymphoma. Implications for staging and prognosis. J Clin Pathol. 2014 May;67(5):431-436. Pubmedid: 24319102.
  • Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res. 2014 Mar;38(3):316-322. Pubmedid: 24374145. Pmcid: PMC4414320.
  • Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's lymphomas, version 2.2014. J Natl Compr Canc Ne. 2014 Jun;12(6):916-946. Pubmedid: 24925202.
  • Deaver D, Cauthen A, Cohen G, Sokol L, Glass F. Excimer laser in the treatment of mycosis fungoides. J Am Acad Dermatol. 2014 Jun;70(6):1058-1060. Pubmedid: 24775402.
  • Yadav BS, George P, Sharma SC, Gorsi U, McClennan E, Martino MA, Chapman J, Chen LM, Prakash G, Malhotra P, Tantravahi SK, Glenn MJ, Werner TL, Baksh K, Sokol L, Morris GJ. Primary non-Hodgkin lymphoma of the ovary. Semin Oncol. 2014 Jun;41(3):e19-e30. Pubmedid: 25023360.
  • Wu H, Zhang L, Shao H, Sokol L, Sotomayor E, Letson D, Bui MM. Prognostic significance of soft tissue extension, international prognostic index, and multifocality in primary bone lymphoma: a single institutional experience. Brit J Haematol. 2014 Jul;166(1):60-68. Pubmedid: 24673481.
  • Deaver D, Naghashpour M, Sokol L. Kikuchi-fujimoto disease in the United States: three case reports and review of the literature [corrected]. Mediterr J Hematol Infect Dis. 2014 Jan;6(1):e2014001. Pubmedid: 24455110. Pmcid: PMC3894840.
  • Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J, Wolfson J, Balser B, Horwitz S. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014 Jan;7:11. Pubmedid: 24456586. Pmcid: PMC4016573.
  • Wu H, Bui MM, Leston DG, Shao H, Sokol L, Sotomayor EM, Zhang L. Clinical characteristics and prognostic factors of bone lymphomas: focus on the clinical significance of multifocal bone involvement by primary bone large B-cell lymphomas. BMC Cancer. 2014 Dec;14:900. Pubmedid: 25465716. Pmcid: PMC4265495.
  • McGraw KL, Basiorka AA, Johnson JO, Clark J, Caceres G, Padron E, Heaton R, Ozawa Y, Wei S, Sokol L, List AF. Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors. PLoS One. 2014 Dec;9(12):e114249. Pubmedid: 25469886. Pmcid: PMC4254997.
  • Harrington L, Sokol L, Holdener S, Shao H, Zhang L. Cutaneous gamma-delta T-cell lymphoma with central nervous system involvement: report of a rarity with review of literature. J Cutan Pathol. 2014 Dec;41(12):936-943. Pubmedid: 25292289.
  • Dalia S, Chavez J, Little B, Bello C, Fisher K, Lee JH, Chervenick P, Sokol L, Sotomayor E, Shah B. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Ann Hematol. 2014 Aug;93(8):1305-1312. Pubmedid: 24590536.
  • Dalia S, Forsyth P, Chavez J, Price S, Shah B, Bello C, Sokol L, Pan E, Sotomayor E, Lee JH, Fisher K, Jaglal M. Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center. Int J Hematol. 2014 Apr;99(4):450-456. Pubmedid: 24584873.
  • Dalia S, Chavez J, Castillo JJ, Sokol L. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: a meta-analysis of observational studies. Leuk Res. 2013 Sep;37(9):1107-1115. Pubmedid: 23809055.
  • Caceres G, McGraw K, Yip BH, Pellagatti A, Johnson J, Zhang L, Liu K, Zhang LM, Fulp WJ, Lee JH, Al Ali NH, Basiorka A, Smith LJ, Daugherty FJ, Littleton N, Wells RA, Sokol L, Wei S, Komrokji RS, Boultwood J, List AF. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proc Natl Acad Sci U S A. 2013 Oct;110(40):16127-16132. Pubmedid: 24043769. Pmcid: PMC3791697.
  • Mailloux AW, Zhang L, Moscinski L, Bennett JM, Yang L, Yoder SJ, Bloom G, Wei C, Wei S, Sokol L, Loughran TP, Epling-Burnette PK. Fibrosis and subsequent cytopenias are associated with basic fibroblast growth factor-deficient pluripotent mesenchymal stromal cells in large granular lymphocyte leukemia. J Immunol. 2013 Oct;191(7):3578-3593. Pubmedid: 24014875. Pmcid: PMC4346227.
  • Horna P, Hamill JR, Sokol L, Glass LF. Primary cutaneous plasmablastic lymphoma in an immunocompetent patient. J Am Acad Dermatol. 2013 Nov;69(5):e274-e276. Pubmedid: 24124865.
  • Patel J, Ho M, Ho V, Bello C, Djulbegovic B, Sokol L, Wetzstein G. Rapid infusion rituximab for maintenance therapy: is it feasible?. Leuk Res Treatment. 2013 Nov;2013:629283. Pubmedid: 24288618. Pmcid: PMC3833187.
  • Zhang Y, Zhang L, Jin X, Zhao H, Hao X, Peker D, Wei S, Sokol L, Moscinski L. Bone marrow involvement as initial presentation of CD8 cytotoxic peripheral T-cell lymphoma with CD20 coexpression and relatively indolent clinical course. Leuk Lymphoma. 2013 May;54(5):1113-1116. Pubmedid: 23035635.
  • Venner CP, Woltosz JW, Nevill TJ, Deeg HJ, Caceres G, Platzbecker U, Scott BL, Sokol L, Sung S, List AF, Karsan A. Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome. Haematologica. 2013 Mar;98(3):409-413. Pubmedid: 22929976. Pmcid: PMC3659949.
  • Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, Lacasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer MA, Naganuma M. Non-Hodgkin's lymphomas, version 1.2013. J Natl Compr Canc Ne. 2013 Mar;11(3):257-272. Pubmedid: 23486452.
  • Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F. A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease. Clin Cancer Res. 2013 May;19(13):3659-3670. Pubmedid: 23659971.
  • Zhang L, Sotomayor EM, Papenhausen PR, Shao H, Moscinski LC, Sandin RL, Caceres G, Valenica H, Malafa M, List AF, Sokol L. Unusual concurrence of T-cell large granular lymphocytic leukemia with Franklin disease (gamma heavy chain disease) manifested with massive splenomegaly. Leuk Lymphoma. 2013 Jan;54(1):205-208. Pubmedid: 22694793.
  • Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J, Caceres G, Billingsley D, Sokol L, Lancet J, Fortenbery N, Zhou J, Eksioglu EA, Sallman D, Wang H, Epling-Burnette PK, Djeu J, Sekeres M, Maciejewski JP, List A. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene. 2013 Feb;32(9):1110-1120. Pubmedid: 22525275. Pmcid: PMC3751397.
  • Bhagat TD, Zhou L, Sokol L, Kessel R, Caceres G, Gundabolu K, Tamari R, Gordon S, Mantzaris I, Jodlowski T, Yu Y, Jing X, Polineni R, Bhatia K, Pellagatti A, Boultwood J, Kambhampati S, Steidl U, Stein C, Ju W, Liu G, Kenny P, List A, Bitzer M, Verma A. miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling. Blood. 2013 Apr;121(15):2875-2881. Pubmedid: 23390194. Pmcid: PMC3624935.
  • Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, Sokol L, Lancet J, Tinsley S, Sweet K, Komrokji R, Jacobsen PB. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013 Apr;21(4):1097-1103. Pubmedid: 23179489.
  • Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF. Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia. 2013 Apr;27(4):977-980. Pubmedid: 23032694.
  • Nyland SB, Krissinger DJ, Clemente MJ, Irby RB, Baab KT, Jarbadan NR, Sokol L, Schaefer E, Liao J, Cuthbertson D, Epling-Burnette P, Paquette R, List AF, Maciejewski JP, Loughran TP. Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study. Leuk Res. 2012 May;36(5):581-587. Pubmedid: 22386729. Pmcid: PMC3312981.
  • Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, Maciejewski JP, List AF, Epling-Burnette PK, Araten DJ. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. Blood Cancer J. 2012 Mar;2(3):e63. Pubmedid: 22829258. Pmcid: PMC3317526.
  • Sokol L, Naghashpour M, Glass LF. Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management. Cancer Control. 2012 Jul;19(3):236-244. Pubmedid: 22710899.
  • Tombleson RL, Ho V, Sokol L, Pinilla J, Wetzstein GA. Optimizing premedications in the prevention of bendamustine infusion-related reactions. Cancer Control. 2012 Jul;19(3):245-247. Pubmedid: 22710900.
  • Bello C, Sokol L. B-cell non-hodgkin lymphoma: targeting in on the future. Cancer Control. 2012 Jul;19(3):171-172. Pubmedid: 22710892.
  • Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012 Feb;30(6):631-636. Pubmedid: 22271479.
  • Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Naganuma M, Dwyer MA. Non-Hodgkin's Lymphomas, version 3.2012. J Natl Compr Canc Ne. 2012 Dec;10(12):1487-1498. Pubmedid: 23221787.
  • McGraw KL, Fuhler GM, Johnson JO, Clark JA, Caceres GC, Sokol L, List AF. Erythropoietin receptor signaling is membrane raft dependent. PLoS One. 2012 Aug;7(4):e34477. Pubmedid: 22509308. Pmcid: PMC3317978.
  • Caceres G, Robey RW, Sokol L, McGraw KL, Clark J, Lawrence NJ, Sebti SM, Wiese M, List AF. HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1. Cancer Res. 2012 Aug;72(16):4204-4213. Pubmedid: 22761337. Pmcid: PMC4557794.
  • Bai F, Villagra AV, Zou J, Painter JS, Connolly K, Blaskovich MA, Sokol L, Sebti S, Djeu JY, Loughran TP, Wei S, Sotomayor E, Epling-Burnette P. Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. Cancer Immunol Immun. 2012 Apr;61(4):523-533. Pubmedid: 21983879. Pmcid: PMC4612510.
  • Sokol L. Fox and Blimp in NK-cell lymphoma. Blood. 2011 Sep;118(12):3192-3193. Pubmedid: 21940827.
  • Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Lacasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wierda WG, Yahalom J, Zafar N. Non-Hodgkin's lymphomas. J Natl Compr Canc Ne. 2011 May;9(5):484-560. Pubmedid: 21550968.
  • Komrokji RS, Al Ali NH, Beg MS, Safa MM, Rollison D, Kharfan-Dabaja M, Bello C, Cultrera J, Sokol L, Pinilla-Ibarz J, Sotomayor EM. Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clin Lymphoma Myeloma Leuk. 2011 Jun;11(3):257-260. Pubmedid: 21658652.
  • Zhou L, McMahon C, Bhagat T, Alencar C, Yu Y, Fazzari M, Sohal D, Heuck C, Gundabolu K, Ng C, Mo Y, Shen W, Wickrema A, Kong G, Friedman E, Sokol L, Mantzaris I, Mantzaris G, Pellagatti A, Boultwood J, Platanias LC, Steidl U, Yan L, Yingling JM, Lahn MM, List A, Bitzer M, Verma A. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res. 2011 Feb;71(3):955-963. Pubmedid: 21189329. Pmcid: PMC3032816.
  • Liu JJ, Zhang L, Ayala E, Field T, Ochoa-Bayona JL, Perez L, Bello CM, Chervenick PA, Bruno S, Cultrera JL, Baz RC, Kharfan-Dabaja MA, Raychaudhuri J, Sotomayor EM, Sokol L. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res. 2011 Dec;35(12):1571-1577. Pubmedid: 21752466.
  • Naghashpour M, Setoodeh R, Moscinski L, Bergier G, McCardle T, Glass F, Sokol L. Nonnecrobiotic necrobiotic xanthogranuloma as an initial manifestation of paraproteinemia and small lymphocytic lymphoma in a patient with Sjögren syndrome. Am J Dermatopathxxx. 2011 Dec;33(8):855-857. Pubmedid: 22042261.
  • Sokol L, Caceres G, Volinia S, Alder H, Nuovo GJ, Liu CG, McGraw K, Clark JA, Sigua CA, Chen DT, Moscinski L, Croce CM, List AF. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Brit J Haematol. 2011 Apr;153(1):24-32. Pubmedid: 21332710. Pmcid: PMC4294220.
  • Johns ME, Moscinski LC, Sokol L. Phenytoin-associated lymphoadenopathy mimicking a peripheral T-cell lymphoma. Mediterr J Hematol Infect Dis. 2010 Sep;2(2):e2010028. Pubmedid: 21415974. Pmcid: PMC3033141.
  • Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Mughal TI, Nademanee A, Porcu P, Press O, Prosnitz L, Reddy N, Smith MR, Sokol L, Swinnen L, Vose JM, Wierda WG, Yahalom J, Yunus F. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Ne. 2010 Mar;8(3):288-334. Pubmedid: 20202462.
  • Sokol L, Caceres G, Rocha K, Stockero KJ, Dewald DW, List AF. JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones. Leuk Res. 2010 Jun;34(6):821-823. Pubmedid: 19819015.
  • van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol. 2010 Aug;28(23):3701-3708. Pubmedid: 20625121.
  • Kiss R, Polgár T, Kirabo A, Sayyah J, Figueroa NC, List AF, Sokol L, Zuckerman KS, Gali M, Bisht KS, Sayeski PP, Keseru GM. Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. Bioorg Med Chem Lett. 2009 Jul;19(13):3598-3601. Pubmedid: 19447617. Pmcid: PMC2812898.
  • Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, Byrd J, Sokol L, Lawrence N, Pireddu R, Dewald G, Williams A, Maciejewski J, List A. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A. 2009 Aug;106(31):12974-12979. Pubmedid: 19470455. Pmcid: PMC2722346.
  • Chen X, Bai F, Sokol L, Zhou J, Ren A, Painter JS, Liu J, Sallman DA, Chen YA, Yoder JA, Djeu JY, Loughran TP, Epling-Burnette PK, Wei S. A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia. Blood. 2009 Apr;113(14):3226-3234. Pubmedid: 19075187. Pmcid: PMC2665892.
  • Alekshun T, Rezania D, Ayala E, Cualing H, Sokol L. Skeletal muscle peripheral T-cell lymphoma. J Clin Oncol. 2008 Jan;26(3):501-503. Pubmedid: 18202425.
  • Epling-Burnette PK, Sokol L, Chen X, Bai F, Zhou J, Blaskovich MA, Zou J, Painter JS, Edwards TD, Moscinski L, Yoder JA, Djeu JY, Sebti S, Loughran TP, Wei S. Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood. 2008 Dec;112(12):4694-4698. Pubmedid: 18791165. Pmcid: PMC2597136.
  • Sokol L, Loughran TP. Large granular lymphocyte leukemia. Curr Hematol Malig Rep. 2007 Oct;2(4):278-282. Pubmedid: 20425381.
  • Sokol L, List A. Immunomodulatory therapy for myelodysplastic syndromes. Int J Hematol. 2007 Nov;86(4):301-305. Pubmedid: 18055335.
  • Alekshun T, Tao J, Sokol L. Aggressive T-cell large granular lymphocyte leukemia: A case report and review of the literature. Am J Hematol. 2007 Jun;82(6):481-485. Pubmedid: 17205534.
  • Behera M, Kumar A, Soares H, Sokol L, Djulbegovic B. Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. Cancer Control. 2007 Apr;14(2):160-166. Pubmedid: 17387301.
  • Rezania D, Sokol L, Cualing H. Classification and treatment of rare and aggressive types of peripheral T-cell/natural killer-cell lymphomas of the skin. Cancer Control. 2007 Apr;14(2):112-123.
  • Alekshun T, Sokol L. Diseases of large granular lymphocytes. Cancer Control. 2007 Apr;14(2):141-150. Pubmedid: 17387299.
  • Rezania D, Sokol L, Cualing H. Classification and treatment of rare and aggressive types of peripheral T-cell/natural killer-cell lymphomas of the skin. Cancer Control. 2007 Apr;14(2):112-123. Pubmedid: 17387296.
  • Sokol L, Loughran TP J. Large granular lymphocyte leukemia. Oncologist. 2006 Mar;11(3):263-273. Pubmedid: 16549811.
  • Naing A, Sokol L, List A. Developmental therapeutics for myelodysplastic syndromes. J Natl Compr Canc Netw. 2006 Jan;4(1):78-82. Pubmedid: 16403406.
  • Alekshun T, Lundbye J, Sokol L, Dailey M. Use of bivalirudin to treat heparin-induced thrombocytopenia in a patient with idiopathic giant-cell myocarditis. Conn Med. 2006 Feb;70(2):69-71. Pubmedid: 16768056.
  • Navas TA, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P, Parmar S, Haghnazari E, Zhou L, Collins R, Kerr I, Nguyen AN, Xu Y, Platanias LC, List AF, Higgins LS, Verma A. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood. 2006 Dec;108(13):4170-4177. Pubmedid: 16940419. Pmcid: PMC1895446.
  • Kurtin S, Sokol L. Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromes. Cancer Control. 2006 Dec;13 Suppl:26-31. Pubmedid: 17242664.
  • Sokol L, Agrawal D, Loughran TP Jr.. Characterization of HTLV envelope seroreactivity in large granular lymphocyte leukemia. Leuk Res. 2005 Apr;29(4):381-387. Pubmedid: 15725471.
  • Sokol L, Agosti SJ. Simultaneous manifestation of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). Am J Hematol. 2004 Feb;75(2):107-109. Pubmedid: 14755378.
  • Sokol L, Loughran TP J. Large granular lymphocyte leukemia and natural killer cell leukemia/lymphomas. CURR TREAT OPTION ON. 2003 Aug;4(4):289-296. Pubmedid: 12943609.
  • McIlwain L, Sokol L, Moscinski L, Saba H. Acute myeloid leukemia mimicking primary testicular neoplasm. Presentation of a case with review of literature. Eur J Haematol. 2003 Apr;70(4):242-245. Pubmedid: 12656749.
  • Sokol L, Stueben ET, Jaikishen J, Lamarche MB. Turner syndrome associated with acquired von Willebrand disease, primary biliary cirrhosis, and inflammatory bowel disease. Am J Hematol. 2002 Jul;70(3):257-259. Pubmedid: 12116986.
  • Sokol L, Prchal J. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med. 2002;346(20):1584-1586. Pubmedid: 12017159.
  • Tees MT, Sokol L. Novel Immunotherapies for B-Cell Lymphomas and Leukemias. Am J Ther. 23(5):e1157-e1181. Pubmedid: 25237982.
  • Tees MT, Sokol L. Novel Pharmacotherapies for B-Cell Lymphomas and Leukemias. Am J Ther. 23(2):e498-e520. Pubmedid: 25549076.

In the News

  • I am Madison Miller and I am a lymphoma survivor
    WFLA, News Channel 8 
    About our patient with lymphoma who established website for young patients with cancer -- The face of a movement. After she was diagnosed with lymphoma, Madison Miller was inspired to start Spark the Way, now she’s working with Moffitt Cancer Center to ignite hope in people with cancer.